
|Articles|October 8, 2012
Aimee Tharaldson, PharmD, Discusses the Biosimilar Pathway
Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts, Inc, discussed the 351K pathway and compared it with the biologic licensing application (BLA) submission route for biosimilar drugs at the Academy of Managed Care Pharmacy's Educational Conference.
Advertisement
Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts, Inc, discussed the 351K pathway compared it with the biologic licensing application (BLA) submission route for biosimilar drugs at the Academy of Managed Care Pharmacy’s Educational Conference. Once more guidance is available from the FDA, there will be more biosimilar approvals, Dr. Tharaldson told the American Journal of Managed Care.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
2
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
3
FDA Accepts NDA for AD109 to Treat of Adults With Obstructive Sleep Apnea
4
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
5






































































































